Chemistry:Nemonapride

From HandWiki
Revision as of 02:14, 6 February 2024 by JTerm (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Antipsychotic medication
Nemonapride
Nemonapride.svg
Clinical data
Trade namesEmilace (Japan )
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
Chemical and physical data
FormulaC21H26ClN3O2
Molar mass387.91 g·mol−1
3D model (JSmol)
  (verify)

Nemonapride (エミレース, Emilace (Japan )) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in May 1991.[1] Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.[2] It has affinity for sigma receptors.

See also

References

  1. "Pharmaceuticals and Medical Devices Safety Information No. 265". Pharmaceuticals and Medical Devices Agency. January 2010. https://www.pmda.go.jp/files/000153478.pdf. 
  2. "Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis". Psychiatry and Clinical Neurosciences (Wiley) 69 (5): 243–258. May 2015. doi:10.1111/pcn.12242. PMID 25296946.